TBI History Severely Undermines Accuracy of Alzheimer's Blood Tests in Veterans
A key FDA-approved Alzheimer's blood biomarker loses more than half its diagnostic accuracy in veterans with prior traumatic brain injury.
Summary
A major Alzheimer's diagnostic blood test — the plasma p-tau217/Aβ42 ratio — performs well in people without brain injury history but may miss more than half of amyloid-positive cases in individuals who previously suffered a traumatic brain injury with extended loss of consciousness. Studying 272 Vietnam War veterans, researchers found accuracy dropped from 90% in those with no TBI to just 63% in those whose TBI involved loss of consciousness longer than five minutes. Even briefer TBI-related loss of consciousness reduced accuracy to 78%. The findings raise urgent concerns about how clinicians interpret Alzheimer's blood tests in veterans, military personnel, contact sport athletes, and others with prior head trauma — a population that may be growing rapidly as blood-based AD testing becomes mainstream.
Detailed Summary
Alzheimer's disease (AD) blood biomarkers represent a major clinical breakthrough, offering a non-invasive, scalable way to detect brain amyloid pathology before symptoms fully emerge. The FDA-approved plasma p-tau217/Aβ42 ratio has shown roughly 90% accuracy in civilian populations for predicting amyloid-PET positivity — the gold standard for detecting Alzheimer's pathology. But a critical question remained: does this accuracy hold in people who have suffered traumatic brain injury (TBI)?
This cross-sectional diagnostic study used data and banked plasma from the DOD Alzheimer's Disease Neuroimaging Initiative, enrolling 272 Vietnam War veterans (mean age 70, 99.3% male) who were cognitively unimpaired or had mild cognitive impairment. Veterans were grouped by TBI history and loss of consciousness (LOC) duration: no TBI, TBI with LOC 0–5 minutes, and TBI with LOC greater than 5 minutes. All had amyloid-PET scans and concurrent plasma samples analyzed between 2024 and 2025.
The results are striking. In veterans with no TBI, the p-tau217/Aβ42 ratio achieved 90% accuracy — consistent with civilian data. But accuracy fell to 78% in those with brief LOC and plummeted to just 63% in those with LOC exceeding five minutes. These findings held when using standalone p-tau217 and the Aβ42/40 ratio, and persisted even after excluding veterans whose TBI occurred within the past decade or when switching to quantitative amyloid-PET thresholds.
The clinical implications are serious. As blood-based AD testing becomes routine, clinicians must recognize that a TBI history may produce false-negative results — meaning amyloid-positive patients could be missed entirely and denied early intervention.
Important caveats apply. The cohort is almost entirely male Vietnam War veterans, limiting generalizability to women and younger or non-military populations. The study is cross-sectional, preventing causal inference. This summary is based on the abstract only, as the full text was not available.
Key Findings
- p-tau217/Aβ42 accuracy drops from 90% (no TBI) to 63% in veterans with TBI and loss of consciousness over 5 minutes.
- Even brief TBI-related loss of consciousness (0–5 min) reduced blood biomarker accuracy to 78%, a statistically significant decline.
- Reduced accuracy persisted regardless of whether TBI occurred within or more than 10 years prior.
- Standalone p-tau217 and Aβ42/40 ratio showed similarly degraded accuracy in TBI-exposed veterans.
- Over half of amyloid-PET-positive TBI cases may receive false-negative blood test results under current protocols.
Methodology
Cross-sectional diagnostic cohort study using data and banked plasma from the DOD ADNI study (enrollment 2013–2020), with plasma analysis performed 2024–2025. Participants were 272 Vietnam War veterans without dementia who had both amyloid-PET imaging and concurrent plasma samples. TBI groups were stratified by loss-of-consciousness duration, and accuracy was assessed against amyloid-PET consensus visual read and quantitative thresholds.
Study Limitations
The cohort is 99.3% male Vietnam War veterans, severely limiting generalizability to women and non-military populations. The cross-sectional design precludes causal conclusions about how TBI mechanistically alters biomarker levels. This summary is based on the abstract only, as the full paper was not accessible; additional methodological details and subgroup analyses may be present in the full text.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: